Prescription ·Strong evidence ·Reviewed May 2026
Telmisartan is a long-acting angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce the risk of cardiovascular events in patients at high cardiovascular risk who cannot tolerate ACE inhibitors. By selectively blocking the angiotensin II type 1 (AT1) receptor, it produces vasodilation and lowers blood pressure without the cough commonly seen with ACE inhibitors. It has one of the longest half-lives in its class, which supports sustained 24-hour blood pressure control with once-daily dosing.
The bottom line
Evidence rating strong. Most-documented uses: treatment of essential hypertension (alone or in combination with other antihypertensives), reduction of cardiovascular morbidity and mortality in patients at high cardiovascular risk who are intolerant of ace inhibitors, sustained 24-hour blood pressure control with once-daily dosing due to a long half-life. 4 sources indexed (2001–2014), with 5 interaction records on file.
Core mechanism
Telmisartan selectively and competitively blocks the binding of angiotensin II to the angiotensin II type 1 (AT1) receptor in vascular smooth muscle, the adrenal cortex, and other tissues. Angiotensin II is the principal vasoactive effector of the renin-angiotensin-aldosterone system, and its actions at the AT1 receptor cause vasoconstriction, aldosterone release, sodium and water retention, sympathetic activation, and vascular and cardiac remodeling. By antagonizing this receptor, telmisartan promotes vasodilation, reduces aldosterone-driven sodium retention, and lowers systemic vascular resistance and blood pressure. Because it acts downstream of angiotensin II generation, its effect is independent of the enzymatic pathway used to form angiotensin II and it does not inhibit the breakdown of bradykinin, which explains the lower incidence of cough compared with ACE inhibitors. Reduced aldosterone activity decreases renal potassium excretion, which is the basis for its risk of hyperkalemia, particularly when combined with potassium supplements, potassium-sparing diuretics, or in renal impairment. Telmisartan is also a partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a property that may contribute modest favorable metabolic effects, though this is not the basis of its approved use.2,1
Can be taken with or without food; food slightly reduces the area under the curve but the effect is not clinically significant. Bioavailability is dose-dependent (roughly 42 to 58 percent). Take at the same time each day for consistent 24-hour blood pressure control. Do not remove a tablet from its blister until immediately before dosing because the tablets are hygroscopic.3
Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Telmisartan.
Recommendation: Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Telmisartan.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
L-Citrulline may add to the blood-pressure-lowering effect of Telmisartan.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
Telmisartan, an angiotensin II receptor blocker, reduces aldosterone secretion and thereby decreases urinary potassium excretion. Co-administration with potassium supplements (or potassium-containing salt substitutes) can produce additive increases in serum potassium, with a real risk of clinically significant hyperkalemia, particularly in patients with chronic kidney disease, diabetes, heart failure, or the elderly.
Recommendation: Avoid routine potassium supplementation and potassium-based salt substitutes unless specifically directed and monitored by a clinician. If potassium must be used, check baseline serum potassium and renal function, then recheck within 1 to 2 weeks of starting or changing either agent. Report muscle weakness, palpitations, or irregular heartbeat promptly.
Garlic extract has modest blood-pressure-lowering and vasodilatory effects. When combined with telmisartan, the antihypertensive effects can be additive, potentially producing excessive blood pressure reduction, dizziness, or symptomatic hypotension, especially at higher garlic doses or when telmisartan therapy is being titrated.
Recommendation: If using garlic extract supplements alongside telmisartan, monitor blood pressure at home and watch for lightheadedness or fainting, particularly on standing. Tell your clinician so antihypertensive dosing can be adjusted if needed. Stop garlic supplements before surgery given additive effects and a theoretical bleeding risk.
Numbered references. Citations throughout the page link here.
In patients with vascular disease or high-risk diabetes, telmisartan was noninferior to ramipril for the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure, with less cough and angioedema; combining the two agents increased adverse events such as hyperkalemia and renal dysfunction without additional benefit.
In ACE-inhibitor-intolerant patients, telmisartan modestly reduced a composite of cardiovascular death, myocardial infarction, and stroke compared with placebo and was well tolerated.
Agents that suppress the renin-angiotensin-aldosterone system, including angiotensin receptor blockers, reduce renal potassium excretion and can cause clinically significant hyperkalemia, with risk amplified by concurrent potassium supplementation, potassium-sparing diuretics, NSAIDs, and impaired kidney function.
Telmisartan's long terminal half-life of about 24 hours supports effective and sustained reduction of systolic and diastolic blood pressure across the full dosing interval, including the early morning period, with once-daily administration.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
